A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Gastrointestinal Malignancies
Phase of Trial: Phase I
Latest Information Update: 24 Dec 2018
At a glance
- Drugs AB-928 (Primary) ; GLS 010 (Primary)
- Indications Colorectal cancer; Gastrointestinal cancer; Oesophageal cancer
- Focus Adverse reactions
- Sponsors Arcus Biosciences
- 26 Oct 2018 Planned initiation date changed from 31 Oct 2018 to 15 Oct 2018.
- 26 Oct 2018 Status changed from not yet recruiting to recruiting.
- 24 Oct 2018 Status changed from planning to not yet recruiting.